Gilead Sciences underperformed the broader health care sector in the most recent trading session, recording a 1.38% decline despite a 0.5% advance in the S&P 500 health care index. Trading activity was modestly elevated, reflecting profit-taking after a four-day winning streak. Investors cited concerns over near-term revenue visibility, particularly as patent expirations for older HIV therapies approach and competition from emerging antiviral entrants intensifies.

In its latest Form 13F filing, Abacus FCF Advisors LLC reduced its stake in Gilead by 16.0%, selling 26,340 shares to leave a holding of 138,674 shares valued at $15.39 million. This trimming made Gilead its 24th largest position, accounting for 2.0% of assets. Meanwhile, Norges Bank initiated a new position worth approximately $2.15 billion, and Ameriprise Financial expanded its stake by nearly 398%, adding 5.39 million shares. Invesco lifted its position by 33.5%, and Assenagon Asset Management increased holdings by 164.4%, underscoring divergent institutional views on Gilead’s medium-term growth trajectory.

Insiders have collectively sold 126,257 shares over the past 90 days, equating to $15.61 million in disposals. Notable transactions include a sale of 3,000 shares by Johanna Mercier on December 15 and 5,000 shares by Director Jeffrey Bluestone on November 28. These sales reduced insider ownership by 0.27% of total shares outstanding, a signal some investors interpret as cautious sentiment from those with direct operational insight.

Gilead reported third-quarter revenue of $7.77 billion, surpassing consensus by $350 million, with adjusted EPS of $2.47, $0.31 above estimates. Revenue rose 3.0% year-over-year, driven by continued demand for hepatitis C and emerging oncology franchises. The company maintained full-year 2025 EPS guidance of 8.05–8.25, implying mid-single-digit growth over analyst consensus of 7.95. Management attributed strength to a robust late-stage pipeline in inflammatory and cell therapy programs, while cautioning on currency headwinds and competitive pricing pressures in antiviral markets.